Treating Depression In Diabetics Helps Control Blood Sugar

June 05, 1997

For patients with diabetes, the goal is tight control. The Diabetes Control and Complications Trial, the landmark diabetes study completed four years ago, concluded unequivocally that keeping a close reign on blood sugar can prevent or delay the kidney, eye and nerve complications that affect patients with diabetes. But for some with the disease, that goal is nearly impossible. Diabetics with depression have a very difficult time managing their blood sugar levels.

Now, investigators at Washington University School of Medicine in St. Louis have found that treating clinical depression can help diabetic patients better control their blood sugar levels. Reporting in the May 22, 1997, issue of Psychosomatic Medicine, the researchers say the anti-depressant drug nortriptyline helps patients control their blood glucose, even though the drug itself tends to raise blood glucose levels. In depressed diabetics, treating depression more than made up for those increases in blood sugar. "The drug had two opposing effects," explains Patrick J. Lustman, Ph.D., principal investigator and associate professor of psychiatry. "It improved depression significantly, but it worsened glucose control in patients who were not depressed. Yet, even in the face of this opposing effect, we found that as depression improved, glucose control did too."

While depression affects about 5 percent of the general population at a given time, the rate is between 15 and 20 percent in patients with diabetes. Lustman and colleagues studied 68 patients with diabetes. All had poor glucose control. Twenty-eight of them also were clinically depressed.

Study participants were divided into four groups. Half of the patients with depression received the drug nortriptyline, a tricyclic anti-depressant. The rest received an inactive substance. Patients who were not depressed also were divided into nortriptyline and placebo groups. Then the patients were followed for eight weeks. This was the first placebo-controlled study to establish that it is possible to treat depression in diabetic patients. "The drug therapy helped bring almost 60 percent of the depressed patients into remission," Lustman says. The study was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and in part by the Sandoz Corp., which provided the nortriptyline.

Better Compliance

Depression has a negative influence on quality of life for anyone, but it can cause additional problems for patients with diabetes because it is closely associated with poor glucose control. Depression also is linked to poor compliance with diabetes treatment.

"There are several theories about why depression has such a negative effect on patients with diabetes," Lustman says. "Depressed patients may not comply with their treatment regimens, or perhaps depression may cause changes in neuroendocrine function, making blood sugar especially difficult to control." Because depression makes it hard for a person to get anything done, it makes sense that the disorder might interfere with measuring blood glucose levels and exercising, watching one's diet or taking insulin. Therefore, treating depression could enable a diabetic patient to better manage diabetes. But Lustman says the study showed that better compliance alone did not explain the better blood sugar control.

The researchers used electronic monitoring devices to determine whether the subjects took their medication. And they used memory glucometers to automatically record the dates and times that patients tested their blood glucose levels. They found that all of the participants followed their prescribed treatment regimens with little fluctuation during the eight weeks of the study.

Meaningful Improvement



In patients who were depressed and who were given nortriptyline, blood glucose levels improved along with psychiatric health. "Each one-point drop in the index that we use to measure depression correlated with a small reduction in blood sugar levels," Lustman says.

He says the new study demonstrates that improvement in depression can translate into a clinically meaningful improvement in glucose control. "Though the point-by-point change is small, the benefits could be substantial because many depressed patients drop more than 20 points in their depression index with effective treatment," he explains.

Because the drug was administered to diabetic patients who were not depressed, it was possible to measure the direct effects of nortriptyline on glucose regulation. "We found that taking nortriptyline increased glucose levels in patients who took the drug but were not depressed," Lustman explains. Other anti-depressants or non-drug interventions such as cognitive psychotherapy that do not have this opposing effect on glucose control may be more effective in diabetes management. Currently, Lustman is studying other treatment methods to see whether he can improve on his recent results. ###

Washington University in St. Louis

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.